Literature DB >> 33000305

Prediction of tumor recurrence and poor survival of ampullary adenocarcinoma using preoperative clinical and CT findings.

Heera Yoen1,2, Jung Hoon Kim3,4, Bo Yun Hur5, Su Joa Ahn1,2, Sun Kyung Jeon1,2, Seo-Youn Choi6, Kyoung Bun Lee7, Joon Koo Han1,2.   

Abstract

OBJECTIVES: To predict poor survival and tumor recurrence in patients with ampullary adenocarcinoma using preoperative clinical and CT findings.
MATERIALS AND METHODS: A total of 216 patients with ampullary adenocarcinoma who underwent preoperative CT and surgery were retrospectively included. CT was assessed by two radiologists. Clinical and histopathological characteristics including histologic subtypes were investigated. A Cox proportional hazard model and the Kaplan-Meier method were used to identify disease-free survival (DFS) and overall survival (OS). A nomogram was created based on the multivariate analysis. The optimal cutoff size of the tumor was evaluated and validated by internal cross validation.
RESULTS: The median OS was 62.8 ± 37.9, and the median DFS was 54.3 ± 41.2 months. For OS, tumor size (hazard ratio [HR] 2.79, p < 0.001), papillary bulging (HR 0.63, p = 0.049), organ invasion on CT (HR 1.92, p = 0.04), male sex (HR 1.59, p = 0.046), elevated CA 19-9 (HR 1.92, p = 0.01), pT stage (HR 2.45, p = 0.001), and pN stage (HR 3.04, p < 0.001) were important predictors of survival. In terms of recurrence, tumor size (HR 2.37, p = 0.04), pT stage (HR 1.76, p = 0.03), pN stage (HR 2.23, p = 0.001), and histologic differentiation (HR 4.31, p = 0.008) were important predictors of recurrence. In terms of tumor size on CT, 2.65 cm and 3.15 cm were significant cutoff values for poor OS and RFS (p < 0.001).
CONCLUSION: Preoperative clinical and CT findings were useful to predict the outcomes of ampullary adenocarcinoma. In particular, tumor size, papillary bulging, organ invasion on CT, male sex, and elevated CA 19-9 were important predictors of poor survival after surgery. KEY POINTS: • Clinical staging based on preoperative clinical information and CT findings can be useful to predict the prognosis of ampullary adenocarcinoma patients. • In terms of survival, tumor size (HR 2.79), papillary bulging (HR 0.63), organ invasion on CT (HR 1.92), male sex (HR 1.59), and elevated CA 19-9 (HR 1.92) were important clinical predictors of poor survival. • Tumor size on CT was of special importance for both poor overall survival and disease-free survival, with optimal cutoff values of 2.65 cm and 3.15 cm, respectively (p < 0.001).

Entities:  

Keywords:  Adenocarcinoma; Ampulla of Vater; Nomograms; Prognosis; Tomography

Mesh:

Year:  2020        PMID: 33000305     DOI: 10.1007/s00330-020-07316-4

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  2 in total

Review 1.  The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates.

Authors:  Katherine E Poruk; D Z Gay; K Brown; J D Mulvihill; K M Boucher; C L Scaife; M A Firpo; S J Mulvihill
Journal:  Curr Mol Med       Date:  2013-03       Impact factor: 2.222

2.  Prognostic analysis of carcinoma of the ampulla of Vater: pancreaticoduodenectomy versus local resection.

Authors:  Jf Feng; Xm Zhou; Wm Mao
Journal:  Hippokratia       Date:  2012-01       Impact factor: 0.471

  2 in total
  4 in total

1.  Long-term survival and pattern of recurrence in ampullary adenocarcinoma patients after curative Whipple's resection: a retrospective cohort study in the National Cancer Center in China.

Authors:  Xiaojie Zhang; Chongyuan Sun; Zefeng Li; Tongbo Wang; Lulu Zhao; Penghui Niu; Chunguang Guo; Xu Che; Yingtai Chen; Dongbing Zhao
Journal:  Am J Cancer Res       Date:  2022-08-15       Impact factor: 5.942

2.  Survival after curative pancreaticoduodenectomy for ampullary adenocarcinoma in a South American population: A retrospective cohort study.

Authors:  Ramiro Manuel Fernandez-Placencia; Paola Montenegro; Melvy Guerrero; Mariana Serrano; Emperatriz Ortega; Mercedes Bravo; Lourdes Huanca; Stéphane Bertani; Juan Manuel Trejo; Patricia Webb; Jenny Malca-Vasquez; Luis Taxa; Alberto Lachos-Davila; Juan Celis-Zapata; Carlos Luque-Vasquez; Eduardo Payet; Eloy Ruiz; Francisco Berrospi
Journal:  World J Gastrointest Surg       Date:  2022-01-27

3.  Ampullary Large-Cell Neuroendocrine Carcinoma, a Diagnostic Challenge of a Rare Aggressive Neoplasm: A Case Report and Literature Review.

Authors:  Eleni Karlafti; Maria Charalampidou; Georgia Fotiadou; Ioanna Abba Deka; Georgia Raptou; Filippos Kyriakidis; Stavros Panidis; Aristeidis Ioannidis; Adonis A Protopapas; Smaro Netta; Daniel Paramythiotis
Journal:  Diagnostics (Basel)       Date:  2022-07-25

4.  Screening for hilar biliary invasion in ampullary cancer patients.

Authors:  Tadayuki Takagi; Mitsuru Sugimoto; Rei Suzuki; Naoki Konno; Hiroyuki Asama; Yuki Sato; Hiroki Irie; Jun Nakamura; Mika Takasumi; Minami Hashimoto; Tsunetaka Kato; Ryoichiro Kobashi; Takumi Yanagita; Yuko Hashimoto; Shigeru Marubashi; Takuto Hikichi; Hiromasa Ohira
Journal:  World J Gastrointest Endosc       Date:  2022-09-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.